VOYAGEUR PHARMACEUTICALS LTD

Voyageur Pharmaceuticals, a TSX Venture mining firm, is expanding lithium exploration and barium sulfate production across Canada & the U.S., poised to meet EV and renewable energy demand.

Voyageur Pharmaceuticals’ declining stock, negative P/E, and lithium‑focused strategy expose key challenges for investors seeking insights into its future viability.

Voyageur Pharmaceuticals partners with Bayer, securing up to $2.35 M in milestone‑based funding and exclusivity to develop U.S. iodine contrast media, aiming to cut supply‑chain dependence and boost medical imaging supplies.

Voyageur Pharmaceuticals’ stock hits a new low after a volatile 2025; negative P/E and high P/B signal investor caution and the need for strategic change.

Voyageur Pharmaceuticals’ volatile TSX stock reflects its lithium & barium sulfate focus—investors eye future growth amid current financial challenges.